All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Venetoclax + Azacitidine
ARA-C + Ida/daunorubicin
L-PAM, pred + bortezomib
The AML Hub was pleased to speak with Amir Fathi, Massachusetts General Hospital, Boston, US. We asked, How would you treat newly diagnosed induction-eligible patients with acute myeloid leukemia?
How would you treat newly diagnosed induction-eligible patients with acute myeloid leukemia?
Fathi highlights that to determine eligibility for intensive cytotoxic chemotherapy, patient's fitness, comorbidities, and functional status are considered. He outlines induction chemotherapy regimens and highlights the two step approach to newly diagnosed AML; intensive chemotherapy, followed by consolidation. Finally, Fathi explains that for less robust patients a gentler regimen including hypomethylating agents or BCL2 inhibitors can be used as an alternative.
Is venetoclax combined with low-dose chemo and HMA safe and efficacious in older patients with AML?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Tapan Kadia, MD Anderson Cancer Center,...
Venetoclax in combination with a HMA has been approved by the European Commission for patients with newly diagnosed AML
On May 25, 2021, the European Commission approved venetoclax with a hypomethylating agent for adult patients with newly diagnosed...
Subscribe to get the best content related to AML delivered to your inbox